Stay updated on Fevipiprant PK in Hepatic Impairment vs Healthy Subjects Clinical Trial
Sign up to get notified when there's something new on the Fevipiprant PK in Hepatic Impairment vs Healthy Subjects Clinical Trial page.

Latest updates to the Fevipiprant PK in Hepatic Impairment vs Healthy Subjects Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record provides details of Novartis’s completed Phase 1 fevipiprant study, including its purpose, eligibility criteria, locations, study design, and outcome measures. It also includes study dates and links to related trial information.SummaryDifference43%

- Check19 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide banner announces that NIH is transitioning to use “Super Intelligence” instead of “Artificial Intelligence,” with updates and FAQs available.SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the full trial details for NCT03048448. This blocks access to the study information and related sections on ClinicalTrials.gov.SummaryDifference17%

Stay in the know with updates to Fevipiprant PK in Hepatic Impairment vs Healthy Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fevipiprant PK in Hepatic Impairment vs Healthy Subjects Clinical Trial page.